Skandinaviska Enskilda Banken Ab (Publ) Madrigal Pharmaceuticals, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 8,955 shares of MDGL stock, worth $3.11 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,955
Previous 35,112
74.5%
Holding current value
$3.11 Million
Previous $9.84 Million
80.68%
% of portfolio
0.01%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding MDGL
# of Institutions
296Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$861 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$709 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$705 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$693 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$686 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.94B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...